NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

TMDI

TMDI US Stock
$1.51
Open: $1.55 High: $1.64 Low: $1.42 Close: $1.5
Range: 2021-04-19 - 2021-04-20
Volume: 2,492,377
Market: Extended-hours
Powered by Finage Stock APIDelayed data
TMDI
  • CEO:
  • Employees:
  • Sector:
  • Industry:
TMDI News
Latest news about the TMDI
  • Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference

    Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference

    View More →
  • Titan Medical to Participate in Upcoming Investor Conferences

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that, David McNally, President, CEO and Chairman and Monique Delorme, CFO of Titan Medical, will participate in two upcoming virtual investor conferences.

    View More →
  • Titan Medical Issues Corporate Update

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced a corporate update in conjunction with its presentation at the H.C. Wainwright Global Life Sciences Conference. David McNally, President, CEO and Chairman of Titan Medical, will provide an overview of the Company and its Enos™ robotic single access surgical system at the conference, which is available for on-demand access on Titan Medical’s website under the "Investors" section.

    View More →
  • Titan Medical to Present at H.C. Wainwright Global Life Sciences Conference

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ robotic single access surgical system at the H.C. Wainwright virtual Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 a.m. ET. A link to the presentation will be available for on-demand access beginning Tuesday, March 9, 2021, on Titan Medical’s website under the "Investors" section.

    View More →
  • Titan Medical Announces Closing of US $23M Bought Deal Offering Including Full Exercise of Over-Allotment Option

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 8,335,000 units of the Company ("Units") sold on a "bought deal" basis for gross proceeds of US $20,004,000 (the "Offering"). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 1,250,250 Units and additional gross proceeds to the Company of US $3,000,600. The aggregate gross proceeds to the Company under the Offering were US $23,004,600.

    View More →
  • Titan Medical Reports Year-End 2020 Financial Results

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the release of its annual financial results for the years ended December 31, 2020 and 2019. During the year ended December 31, 2020, the Company generated revenue of $20.0 million, resulting from development and license agreements with Medtronic plc, and raised aggregate net proceeds of approximately $22.0 million from equity financings and approximately $2.7 million from the exercise of warrants. The Company also received a $1.5 million 8% senior secured loan from an affiliate of Medtronic.

    View More →
  • Titan Medical Announces Filing of Final Short Form Prospectus

    Titan Medical Inc. ("Titan" or the "Company") (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed and been receipted for a final short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company ("Units") on a "bought deal" basis, at a price of US$2.40 per Unit (the "Offering Price") for aggregate gross proceeds of US$20,004,000 (the "Offering"). Bloom Burton Securities Inc. (the "Underwriter") will act as underwriter for the Offering.

    View More →
  • Titan Medical Launches "Titan Living Labs" Showcasing a Behind-the-Scenes Look at Product Development

    Titan Medical Inc. launched Titan Living Labs, a behind-the-scenes look at development of technology for robotic assisted single access surgery.

    View More →
  • Titan Medical to Report Year-End 2020 Financial Results and Host Webcast on February 22, 2021

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its fourth quarter and year-end financial results prior to market opening Monday, February 22, 2021 and management will host an investor audio webcast at 4:30 pm ET to discuss financial results and business highlights. Speakers will include David J. McNally, President and Chief Executive Officer, Monique L. Delorme, Chief Financial Officer, and Perry A. Genova, Ph.D., Senior Vice President, Research and Development.

    View More →
  • Titan Medical Announces Filing of Preliminary Short Form Prospectus

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed a preliminary short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company ("Units") on a "bought deal" basis, at a price of US$2.40 per Unit (the "Offering Price") for aggregate gross proceeds of US$20,004,000 (the "Offering"). Bloom Burton Securities Inc. (the "Underwriter") will act as underwriter for the Offering.

    View More →
  • Titan Medical Announces Upsize to Previously Announced Bought Deal Offering

    Titan Medical Inc. ("Titan" or the "Company") (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the "Underwriter") to increase the amount of its previously announced "bought deal" offering. The Underwriter has now agreed to purchase, on a "bought deal" basis, 8,335,000 units of the Company (the "Units") at a price of $2.40 per Unit (the "Offering Price") for aggregate gross proceeds of $20,004,000 (the "Offering").

    View More →
  • Titan Medical Announces Us $15 Million Bought Deal Offering

    Titan Medical Inc. ("Titan" or the "Company") (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the "Underwriter") pursuant to which the Underwriter has agreed to purchase, on a "bought deal" basis, 6,250,000 units of the Company (the "Units") at a price of $2.40 per Unit (the "Offering Price") for aggregate gross proceeds of $15,000,000 (the "Offering").

    View More →
  • Titan Medical Announces Closing of US $11.5M Bought Deal Offering Including Full Exercise of Over-Allotment Option

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company ("Units") sold on a "bought deal" basis for gross proceeds of approximately US $10,000,000.00 (the "Offering"). Bloom Burton Securities Inc. (the "Underwriter") acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 967,741 Units and additional gross proceeds to the Company of approximately US $1,500,000. The aggregate gross proceeds to the Company under the Offering were approximately US $11,500,000.

    View More →
  • IIROC Trading Halt - TMD

    TORONTO, Jan. 25, 2021 /CNW/ - The following issues have been halted by IIROC: Company: Titan Medical Inc.

    View More →
  • Titan Medical Announces US$10 Million Bought Deal Offering

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the "Underwriter") pursuant to which the Underwriter has agreed to purchase, on a "bought deal" basis, 6,451,613 units of the Company (the "Units") at a price of US$1.55 per Unit (the "Offering Price") for aggregate gross proceeds of US$10,000,000 (the "Offering").

    View More →
  • Titan Medical Provides Regulatory Update

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company has received a written response from the U.S. Food & Drug Administration ("FDA") to its Request for Information in accordance with Section 513(g) of the U.S. Federal Food, Drug and Cosmetic Act ("FD&C Act"), regarding the regulatory requirements applicable to its robotically assisted surgical device ("RASD"), the Enos™ Robotic Single Access System. While the FDA's response to a 513(g) request does not constitute a classification decision, the FDA has indicated that, based on information provided to the agency, the Enos system is appropriate for classification through the De Novo pathway.

    View More →
  • Titan Medical Reports Full Compliance with Nasdaq Listing Criteria

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that on December 24, 2020, the Company received written notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has cured the bid price deficiency and has regained full compliance with all applicable criteria for continued listing and trading on The Nasdaq Capital Market.

    View More →
  • Titan Medical: Driving Toward Improved Patient Outcomes Through Robotic Single Access Surgery

    Titan Medical will be speaking at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020.The use of multi-port robotic surgical systems is becoming more widely adopted in urology, gynecology, and general surgery. This type of surgical procedure (multi-port) is performed by making multiple incisions for insertion points into the body.Robotic-assisted abdominal surgery is only expected to grow. In fact, the global surgical robotics market is estimated to be about $12 billion by 2025.While acceptance of multi-port robotic systems is increasing among surgeons, there continues to be an opportunity to reduce the number of incisions and related trauma for patients, while expanding the availability of robotic surgical technologies beyond traditional hospital settings.For medical technology company Titan Medical Inc. (NASDAQ: TMDI) (TMX:TMD), single access surgery is the next generation of medical robotic technology.Enos™ Robotic Single Access Surgical System The Enos surgical system ‒ its name derived from the Greek word meaning "of one" ‒ is Titan Medical's robotic single access surgery system in development.Titan's goals in creating its robotic-assisted single access system are to improve patient outcomes, lower operating room costs, and create applied technology that is easy-to-use and effective. Titan Medical is addressing the challenge of creating a system that allows for multiple high-definition cameras, lighting, and two articulating arms with tools to be delivered through a single 25 mm incision.How It Works As opposed to multi-port surgical systems, the single access system that Titan is designing works by using one incision around the umbilicus. The potential result of this system is near-scarless surgery, less trauma and pain for patients, and faster recovery times.The benefits of using robotic technology for surgery include: * Improved consistency of patient outcomes * High-definition 3D visualization for optimal visibility and patient safety * Increased dexterityThe Enos system is being designed specifically with hospital considerations in mind. The system is designed to be easy to use and position, improve operating room efficiency, and lower operating room costs. And its ergonomic design will enable comfortable surgical posture, even during long procedures.The system also has integrated software for simulation surgeon training and accreditation. Preparing For A Pre-Clinical And Clinical Future The company recently announced that it completed its first technical milestone under a development and license agreement with Medtronic plc (NYSE: MDT) and Titan has received a $10 million payment. Under the agreement with Medtronic, Titan Medical will be able to further leverage the developed technology as part of its robotic single-access surgical system.As a technology still in development, the Enos system has not yet had its first application in human surgery. The system still has some important phases of development to undergo between now and then. "Over the next couple of years we will be moving from development into preparation for pre-clinical and clinical use to ensure that we have a robotic surgical system safe and effective for use in humans," said David McNally, President & CEO of Titan Medical.Titan's Enos robotic single access surgical system has not been cleared or approved by the U.S. Food and Drug Administration, nor any other regulatory authority in any other jurisdiction. To learn more about Titan Medical and the Enos system, click here.See more from Benzinga * Click here for options trades from Benzinga * Gage Cannabis On Their Goal To Dominate A Strategic Cannabis Market: Michigan * Lantern Pharma's A.I. Platform Is Helping To Transform The Probability Of Success In Oncology Drug Development & Clinical Trials(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Microbix Announces Addition to Board of Directors

    Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences LeaderMISSISSAUGA, Ontario, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Mr. Anthony J. Giovinazzo, an accomplished leader in the international life sciences industry, has joined its Board of Directors. Mr. Giovinazzo joined the Board of Directors effective today, and was also appointed as a member of the Audit Committee and the Human Resources, Compensation & Governance Committee.Mr. Giovinazzo has over 40 years of life sciences experience and is an internationally-recognized expert in life sciences intellectual property, drug development, and product commercialization. As CEO of Cynapsus Therapeutics Inc., he co-invented and led the development and commercialization of the now Health Canada and U.S. FDA approved Parkinson’s Disease drug Kynmobi™, acquired by Sunovion Pharmaceuticals for CDN$ 841 million in 2016. Among other industry awards, he was the inaugural recipient of the Bloom Burton Award in 2017.Mr. Giovinazzo is a Chartered Director and is Audit Committee Certified, both from The Directors College, a degree granting affiliate of McMaster University. He has also completed Harvard Business School’s program for Leadership and Strategy in Pharmaceuticals & Biotech, IMD’s Master of Business Administration (MBA) program, York University’s Osgoode Hall Law School Certificate Studies in Canadian Law program, and McMaster University’s B.A. of Economics and Accounting program. Mr. Giovinazzo currently serves as executive chairman of Sublimity Therapeutics (Holdings) Ltd., a private company, as a director of Pond Technologies Holdings Inc. (TSXV: POND), and as a director of Titan Medical Inc. (TSX: TMD; NASDAQ: TDMI).Martin Marino, independent chair of Microbix’s Board of Directors, commented, “I’m delighted to welcome Anthony on behalf of Microbix’s Directors, Management, Staff, and Shareholders. Anthony will add his drive, connectivity, broad perspectives, and expertise to Microbix’s board-level leadership. His selection follows a formal process by which a special committee of our board evaluated multiple qualified candidates.”Anthony Giovinazzo also remarked about his decision to join the board, “I’ve observed how Microbix has been evolving its business and have been impressed. Microbix is now well advanced with its transformation into an inventor, manufacturer, and marketer of innovative, proprietary, branded, and regulated medical devices to support the global diagnostics industry. I look forward to helping to accelerate the pace of value creation by Microbix and ensuring that shareholders are fully rewarded.”Upon his appointment, Mr. Giovinazzo is being granted 100,000 options to purchase common shares. The options have an exercise price of $0.46, a term of five years and vest at the end of three years.About Microbix Biosystems Microbix develops proprietary biological and technology solutions for human health and well-being, with about 80 skilled employees and sales growing from a base of approximately $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 20 countries, distributed by Alpha-Tec Systems, Inc., Diagnostic International Distribution S.p.A., Labquality Oy, The Medical Supply Company of Ireland, and R-Biopharm AG. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport media to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQB, and headquartered in Mississauga, Ontario, Canada.Forward-Looking Information This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, all discussion regarding Mr. Giovinazzo or his qualifications, his or others’ views, the role or actions of the board, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to domestic or foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.Please visit www.microbix.com or www.sedar.com for recent Microbix news and filings.For further information, please contact Microbix at:Cameron Groome, CEO (905) 361-8910Jim Currie, CFO (905) 361-8910Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com Copyright © 2020 Microbix Biosystems Inc. Microbix®, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. Kynmobi™ is a trademark of Sunovion Pharmaceuticals Inc.

    View More →
  • Titan Medical to Present at the Benzinga Global Small Cap Conference

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ single access surgical system to a live virtual audience at the Benzinga Global Small Cap Conference on Wednesday, December 9, 2020 at 1:30 p.m. ET. To view Mr. McNally’s presentation, please register in advance at: https://www.benzinga.com/events/small-cap/.

    View More →